Global /Norway /Healthcare /Medical Devices /GENT
chevron_leftBack

Gentian Diagnostics ASA

GENT
OSL: GENT Delayed
48.00NOK -1.4%
4.61 USD
As of 24 April 2025, Gentian Diagnostics ASA has a market cap of $72.18M USD, ranking #22936 globally and #158 in Norway. It ranks #2294 in the Healthcare sector, and #275 in the Medical Devices industry.
Global Rank
22936
Country Rank
158
Sector Rank
2294
Industry Rank
275
Key Stats
Market Cap
$72.18MUSD
751.07M NOK
Enterprise Value
$65.01MUSD
676.37M NOK
Revenue (TTM)
$14.62MUSD
152.07M NOK
EBITDA (TTM)
$1.79MUSD
18.6M NOK
Net Income (TTM)
$4.35MUSD
45.29M NOK
EBITDA Margin
12%
Profit Margin
30%
PE Ratio
17.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Matti Heinonen open_in_new
Employees
63
Founded
2001
Website
gentian.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.4% 4.1% 5.9% 16% 18% 33%
Upcoming Earnings
Earnings Date
Wed, May 7

Markets

Exchange Ticker Price
Euronext Oslo Børs
MIC: XOSL
PRIMARY
GENT
Gentian Diagnostics AS
ISIN: NO0010748866
Shares Out.:
15.422M1 Shares Float: 8.73M2
TV:
SA:
YF:
GF:
BA:
MS:
48.00 NOK
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure, which is in product development phase. In addition, the company provides faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.

Similar Companies

Industry: Medical Devices (Norway)
Name
Market Cap diff.
Medistim ASA
MEDI
$284.11M
2.96B NOK
294%
Lifecare AS
LIFE
$14.29M
148.69M NOK
-80%
Observe Medical ASA
OBSRV
$1.55M
16.18M NOK
-98%
Industry: Medical Devices (Global)
Name
Market Cap diff.
Abbott Laboratories
ABT
$225.18B
312K%
Boston Scientific Corp.
BSX
$146.31B
203K%
Stryker Corp.
SYK
$136.3B
189K%
Medtronic plc
MDT
$107.41B
149K%
Siemens Healthineers AG
SHL
$58.0B
50.97B EUR
80K%